1230PDPHASE 1B STUDY OF ORAL DUAL-PI3K/MTOR INHIBITOR GDC-0980 IN COMBINATION WITH CARBOPLATIN (CARBO)/PACLITAXEL (PAC) ± BEVACIZUMAB (BEV) AND CISPLATIN (CIS)/PEMETREXED (PEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS AND NSCLC
Published 2017 View Full Article
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now